StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SHALBY.NS$169.29-2.04%
Fair $169.29+0.0%

SHALBY.NS

Shalby Limited

Healthcare / Medical Care FacilitiesNSE

$169.29

-3.52 (-2.04%)

Fairly Valued+0.0%Fair Value $169.29Fund rank 24/100 · Data gapFallback financials|
SA 48/C
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-275.1M · quality 39.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 7/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

48/100

C

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 0.6%, below the 5% threshold
Thesis & Journal · SHALBY.NSLocal privado en este navegador · Shalby Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$18.2B

P/E

217.0x

↑

EV/EBITDA

14.4x

↑

ROE

0.6%

↑

Gross Margin

41.2%

↓

Debt/Equity

0.48

↑
52-Week Range$169
$126$275

TradingView lightweight chart

SHALBY.NS price, volumen y niveles de valoración

Último $168.81Periodo -29.5%
Fair value: $169.29

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+15.6%

FCF CAGR

—

FCF margin

-7.0%

FCF / Net income

-12.18x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $10.81B · net income $62.2M · FCF $-757.9M

2022-FY → 2025-FY

Gross margin

41.2%-2.3% pts

Operating margin

7.2%-4.6% pts

Net margin

0.6%-7.2% pts

FCF margin

-7.0%+1.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$10.81B$10.81B$9.28B$8.00B$6.99B
Net Income$62.2M$62.2M$840.8M$677.0M$541.3M
EBITDA$1.57B$1.57B$1.95B$1.58B$1.28B
EPS0.580.587.836.305.00
Gross Margin41.2%41.2%45.6%45.6%43.6%
Operating Margin7.2%7.2%13.8%11.7%11.8%
Net Margin0.6%0.6%9.1%8.5%7.7%
Balance Sheet
Debt/Equity0.480.480.380.190.20
Current Ratio1.251.25———
Cash Flow
Free Cash Flow$-757.9M$-757.9M$-275.1M$492.9M$-564.8M
Returns
ROE0.6%0.6%8.4%7.3%6.2%
Valuation
P/E217.04217.0434.1422.3726.57
EV/EBITDA14.4214.4216.5310.6412.15
P/B1.831.832.871.631.64
Growth & Yield
Revenue Growth16.4%16.4%16.1%14.4%—
EPS Growth-92.6%-92.6%24.3%26.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

196.0%

muy exigente

EPS terminal req.

$15.02

Spread vs growth

-288.7%

5Y implied EPS CAGR

99.2%

muy exigente

EPS terminal req.

$18.18

Spread vs growth

-191.8%

10Y implied EPS CAGR

48.0%

muy exigente

EPS terminal req.

$29.27

Spread vs growth

-140.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -15.6%

Total return

-15.6%

Start / end P/E

25.5x → 291.6x

EPS bridge

7.83 → 0.58

Residual

-964.4%

EPS growth-92.6%
Multiple rerating+1041.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-964.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.